Novo Nordisk's New US Chief Addresses Rival Weight-Loss Pill from Eli Lilly

Apr 01, 2026 21:02 UTC

NOVO, LLY

Short term

Novo Nordisk's US operations executive Jamey Millar discusses the recent US approval of Eli Lilly's obesity pill and the evolving GLP-1 market. The conversation highlights strategic responses to competition in the weight-loss drug sector.

Jamey Millar, Novo Nordisk's US operations executive, discusses Eli Lilly's new obesity pill approval.
Novo introduces a subscription model to improve patient access and treatment adherence.
The GLP-1 category is expanding, with increased competition in the weight-loss drug market.
Millar highlights Novo's commitment to innovation and market leadership.
The healthcare sector is closely monitoring Novo's strategic responses to industry changes.

Jamey Millar, Executive Vice President of Novo Nordisk's US operations, recently addressed the implications of Eli Lilly's newly approved obesity pill in the United States. Speaking on 'The Close,' Millar outlined Novo's strategic approach to the expanding GLP-1 category and the introduction of a subscription model to enhance patient access. The approval of Lilly's rival product marks a significant development in the competitive landscape of weight-loss therapies. Millar emphasized Novo's commitment to innovation and market leadership, noting the company's ongoing efforts to adapt to shifting industry dynamics. The GLP-1 market has seen rapid growth, driven by increasing demand for effective obesity treatments. Novo's subscription model aims to streamline patient care and improve adherence to treatment regimens. As the healthcare sector continues to evolve, Novo's strategies will be closely watched by investors and industry stakeholders.